Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) Profit After Tax (2016 - 2025)

Perspective Therapeutics' Profit After Tax history spans 16 years, with the latest figure at -$26.0 million for Q3 2025.

  • For Q3 2025, Profit After Tax fell 71.73% year-over-year to -$26.0 million; the TTM value through Sep 2025 reached -$107.5 million, down 68.47%, while the annual FY2024 figure was -$80.0 million, 71.99% down from the prior year.
  • Profit After Tax for Q3 2025 was -$26.0 million at Perspective Therapeutics, down from -$21.5 million in the prior quarter.
  • Across five years, Profit After Tax topped out at -$371000.0 in Q1 2023 and bottomed at -$41.8 million in Q4 2024.
  • The 5-year median for Profit After Tax is -$10.4 million (2023), against an average of -$11.0 million.
  • The largest annual shift saw Profit After Tax surged 72.46% in 2023 before it plummeted 3211.05% in 2024.
  • A 5-year view of Profit After Tax shows it stood at -$1.6 million in 2021, then fell by 19.7% to -$1.9 million in 2022, then plummeted by 1185.16% to -$24.7 million in 2023, then tumbled by 69.52% to -$41.8 million in 2024, then skyrocketed by 37.91% to -$26.0 million in 2025.
  • Per Business Quant, the three most recent readings for CATX's Profit After Tax are -$26.0 million (Q3 2025), -$21.5 million (Q2 2025), and -$18.2 million (Q1 2025).